Kenneth Brodsky, DO
Internal Medicine · Auburn, MENPI 1134159593
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Boehringer Ingelheim at 26.0% of the total. Reporting peaked in 2019 at $426 and has fallen 97.2% since, to $12 in 2021.
Across 32 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$124
- AbbVie$62
- Pfizer$52
- Sanofi-aventis U.S. LLC$49
- GSK$42
- Amgen$40
- plus $108 from 6 others
What the payments were for
- Food & beverage$477100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $124 |
| AbbVie(2 entities) | 4 | $62 |
| Pfizer | 4 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| GSK | 3 | $42 |
| Amgen | 2 | $40 |
| Merck | 2 | $31 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Novo Nordisk | 1 | $11 |
How this compares
$477 in reported general payments places this provider in the 85th percentile of 445 internal medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 197 | $271,772 |
| XareltoRivaroxaban | 74 | $94,083 |
| FarxigaDapagliflozin Propanediol | 56 | $76,355 |
| TrulicityDulaglutide | 52 | $70,556 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $57,186 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $56,850 |
| JardianceEmpagliflozin | 36 | $48,405 |
| JanuviaSitagliptin Phosphate | 28 | $36,493 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $27,773 |
| LinzessLinaclotide | 25 | $24,296 |
| OzempicSemaglutide | 13 | $22,699 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $20,733 |
| InvokanaCanagliflozin | 30 | $10,546 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $8,874 |
| MyrbetriqMirabegron | 18 | $8,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52 | $271,772197 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $42 | $134,769133 claims |
| AstraZenecaFarxiga, Symbicort | $14 | $83,10271 claims |
| Lilly USA, LLCTrulicity | $17 | $70,55652 claims |
| Boehringer IngelheimJardiance | $124 | $48,40536 claims |
| MerckJanuvia | $31 | $36,49328 claims |
| AbbVieLinzess | $62 | $24,29625 claims |
| Novo NordiskOzempic | $11 | $22,69913 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $8,55918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 445 internal medicine providers in Maine.
Other internal medicine in Auburn
- Edwin TanAuburn$6K
- James OzonAuburn$399
- Paul RaczynskiAuburn$384
- Diana TrofimovitchAuburn$373
- Nananda ColPortland$124K
- Heidi DeblockPortland$27K
- Gene ChengAugusta$22K
- Elizabeth DennisWestbrook$17K
- Hassan AbouleishHoulton$15K
- Peter GuzzettiAugusta$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.